From the Mercy Health Research and Ryan Headache Center, St. Louis, MO (Dr. Smith); Neurological Associates of Tulsa, Tulsa, OK (Dr. Blumenthal); Diamond Headache Clinic (Dr. Diamond); New York Headache Center, New York, NY (Dr. Mauskop); and GlaxoSmithKline, Research Triangle Park, NC (Drs. Ames, McDonald, Lener, and Burch).
Sumatriptan/Naproxen Sodium for Migraine: Efficacy, Health Related Quality of Life, and Satisfaction Outcomes
Article first published online: 9 MAY 2007
Headache: The Journal of Head and Face Pain
Volume 47, Issue 5, pages 683–692, May 2007
How to Cite
Smith, T., Blumenthal, H., Diamond, M., Mauskop, A., Ames, M., McDonald, S., Lener, S. and Burch, S. (2007), Sumatriptan/Naproxen Sodium for Migraine: Efficacy, Health Related Quality of Life, and Satisfaction Outcomes. Headache: The Journal of Head and Face Pain, 47: 683–692. doi: 10.1111/j.1526-4610.2007.00790.x
- Issue published online: 9 MAY 2007
- Article first published online: 9 MAY 2007
- Accepted for publication January 2, 2007.
- quality of life
Objective.—To describe the pain relief, satisfaction, and health-related quality of life results of moderate or severe migraines treated with a sumatriptan/naproxen sodium combination tablet.
Methods.—Sumatriptan and naproxen sodium as a single-dose formulation tablet was used to treat moderate to severe migraines over a 12-month period in a phase 3, open-label, multicenter study (n = 565) in patients with at least 6 months' history of migraine headaches.
Results.—Seventy percent of all attacks were treated with 1 dose of sumatriptan/naproxen sodium. Overall subjects treated 24,485 attacks; of these, 81% attacks achieved pain relief and 60% pain-free by 2 hours. At 3 months, the percentage of patients satisfied or very satisfied increased from baseline on all 8 Patient Perception of Migraine Questionnaire (PPMQ) items and remained high throughout the study. Mean Migraine-Specific Quality of Life Questionnaire (MSQ) domain scores also increased by 13–15 points from baseline during this time and remained high.
Conclusions.—Sumatriptan/naproxen sodium provides consistent relief of migraine attacks over 12 months, resulting in improved patient satisfaction and migraine specific quality of life.